NBAA and Dozen Aviation Groups Back FAA Proposal to Ease Medical Certification for Non-Insulin Diabetic Pilots

NBAA, joined by a dozen other aviation groups, announced support for a Federal Aviation Administration notice of proposed rulemaking (NPRM) that would ease medical certification requirements for pilots with non-insulin dependent diabetes mellitus (NIDDM). Under current rules, any applicant with a medical history or clinical diagnosis of diabetes requiring insulin or another hypoglycemic drug for control faces a specifically disqualifying medical condition and must obtain a special issuance authorization from the FAA.

The NPRM proposes amendments to §§ 67.113(a), 67.213(a), and 67.313(a), which govern first-class, second-class, and third-class medical certificates respectively, that would allow pilots with diabetes controlled through non-insulin medications to obtain a medical certificate. The FAA estimates the change, if enacted, could save between $39.7 million and $80.19 million in industry labor hours over five years.

Mark Larsen, CAM, NBAA's director of safety and flight operations, said "NBAA applauds the FAA's efforts to update their regulations and standards to meet today's science," adding that the notice "highlights the FAA's perspective that today's medicine proves the safety case that pilots with non-insulin dependent diabetes with their condition controlled by non-insulin medication are fit for duty without the need to undergo additional onerous, time-consuming FAA review." The coalition of industry groups stated that NIDDM "is now well-understood and effectively managed by modern medicine" and represents "a prime example of a condition that AMEs can be entrusted to certify or to defer under the privileges of their designation by applying an appropriate aeromedical standard, without the need for a special issuance authorization." Larsen added that the reforms "can streamline the certification process for qualified pilots, reduce unnecessary administrative burdens for applicants and the FAA, and allow aeromedical resources to remain focused on cases that require special review."

This proposal belongs to a broader effort to align FAA medical certification with current medical practice, moving conditions once treated as automatically disqualifying into the routine purview of aviation medical examiners (AMEs). Special issuance authorizations exist to give the FAA direct oversight of conditions considered higher-risk; shifting NIDDM out of that pathway reflects an industry argument that modern non-insulin treatment has made the condition predictable enough for AMEs to certify or defer without separate federal review.

For the pilot population, the practical effect would be fewer applicants waiting on FAA-level special issuance processing, and for the agency, a narrower caseload concentrated on conditions that still carry greater uncertainty. The estimated labor-hour savings cited by the FAA underscore how much of the current burden is administrative rather than clinical.

What happens next depends on the rulemaking process itself: whether the NPRM proceeds to a final rule, what comment period and revisions it undergoes, and whether the amendments to §§ 67.113(a), 67.213(a), and 67.313(a) are adopted as proposed or modified in response to industry and public input.